Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: belimumab

Mitigating Drug Shortages: FDA Officials Say Communication Is Crucial

Thomas R. Collins  |  December 13, 2022

PHILADELPHIA—The most vital component of avoiding drug shortages is early communication, officials from the U.S. Food & Drug Administration (FDA) said in a session at ACR Convergence 2022 in November. “Early notification is key in order to prevent and mitigate shortages,” said Hyun Son, PharmD, a member of the Drug Shortage Staff with the FDA…

Filed under:ACR ConvergenceDrug UpdatesLegislation & AdvocacyMeeting ReportsProfessional Topics Tagged with:ACR Convergence 2022Drug shortageFDA

Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?

Samantha C. Shapiro, MD  |  December 6, 2022

How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?

Filed under:ACR ConvergenceBiologics/DMARDsConditionsDrug UpdatesMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022belimumabcyclophosphamideLupus nephritismycophenolate mofetilprednisonepregnancyreproductive carerituximabsystemic lupus erythematosus (SLE)tocilizumabvoclosporin

The Complexity of SLE Drug Research

Ruth Jessen Hickman, MD  |  December 6, 2022

PHILADELPHIA—On Saturday, Nov. 12, at ACR Convergence 2022, Joan T. Merrill, MD, director of clinical projects in the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Foundation in Oklahoma City, gave a presentation on the future of drug development and treatments for systemic lupus erythematosus (SLE). She described how an in-depth understanding of…

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2022LupusSLETreatment

Updated Perioperative Guideline Released: Recommendations Balance Risks of Infection & Disease Flare

Ruth Jessen Hickman, MD  |  September 13, 2022

The 2017 recommendations are updated to reflect changes in medical literature, as well as to include newly approved drugs.

Filed under:Clinical Criteria/GuidelinesConditions Tagged with:guidelinePerioperative Management of Anti-Rheumatic Medications in Patients with Rheumatic Diseases Undergoing Elective Total Hip or Knee Arthroplastytotal hip arthroplastytotal knee arthroplasty

What’s New in SLE: Pathogenesis & Novel Therapies

Samantha C. Shapiro, MD  |  September 8, 2022

Thomas Dörner, MD, reviewed the current state of systemic lupus erythematosus (SLE) management, providing updates on novel therapies and insights into the pathogenesis of SLE.

Filed under:ConditionsMeeting ReportsSystemic Lupus Erythematosus Tagged with:anifrolumabbelimumabEULARPathogenesisSLEsystemic lupus erythematosus (SLE)voclosporin

Dermatologist, Rheumatologist Discuss Refractory Cutaneous Lupus Case

Richard D. Sontheimer, MD, & Samantha C. Shapiro, MD  |  September 5, 2022

As a dermatologist/internist with a career-long subspecialty interest in the cutaneous manifestations of the rheumatic diseases, I found the case of refractory acute cutaneous lupus by Samantha C. Shapiro, MD, in the June 2022 issue of The Rheumatologist intriguing in several ways, and I felt my perspectives on this case might provide additional educational value…

Filed under:ConditionsOpinionSpeak Out RheumSystemic Lupus Erythematosus Tagged with:case reportcutaneous lupus erythematosus (CLE)Dermatologydiagnostic imagingimage caseimage case reportletter to the editor

Difficult-to-Treat Lupus: When & How to Use New Therapies

Samantha C. Shapiro, MD  |  July 21, 2022

Clinicians have numerous treatment options for SLE; in a EULAR 2022 session, some of the newer therapies were reviewed.

Filed under:ConditionsEULAR/OtherMeeting ReportsSystemic Lupus Erythematosus Tagged with:belimumabEULARHCQHydroxychloroquine (HCQ)rituximabSLEsystemic lupus erythematosus (SLE)

The Ins & Outs of Patient Assistance Programs

Samantha C. Shapiro, MD  |  March 3, 2022

Although effective against rheumatic disease, biologic therapies come with hefty price tags. Patient assistance programs can be a useful resource to help under- and uninsured patients get the drugs they need.

Filed under:Biologics/DMARDsDrug UpdatesPractice Support Tagged with:biologic therapiesdrug costsfederally qualified health centerpatient assistance programs (PAP)patient careuninsured Americans

‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report

The UNC Rheumatology Fellowship Program: Leah Bettner, MD; Shruti Chandramouli, MD; Christopher Overton, MD; Astia Allenzara, MD; Michael Cunningham, MD; & Luis Palomino, MD  |  February 8, 2022

Neutrophil extracellular traps (NETs) contribute to the pathogenesis of multiple autoimmune diseases. And research has shown that patients with antiphospholipid syndrome (APS) have higher levels of circulating anti-NET antibodies than healthy controls, indicating a potential biomarker.

Filed under:ConditionsOther Rheumatic ConditionsResearch Rheum Tagged with:anti-NET antibodiesAntiphospholipid Antibody Syndrome (APS)APScellsNETosisneutrophil extracellular trapsRheumMadness

Advances in Rheumatology & Challenges that Remain Spotlighted in ACR Convergence 2021 Closing Session

Vanessa Caceres  |  December 2, 2021

The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2021

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 15
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences